A multicenter, non-randomized, open label study to evaluate the efficacy and security of Ibrutinib followed by ofatumumab consolidation in previously untreated patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).
Phase of Trial: Phase II
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Ibrutinib (Primary) ; Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 27 Jul 2017 New trial record